welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne Scholarship Program. This is the second year of the scholarship program which was created to recognize exceptional individuals with Duchenne muscular dystrophy as they pursue their post-secondary education. Twenty-three recipients were chosen by an independent selection committee comprised of Duchenne community members based on each applicant’s community involvement and a personal essay. Each of the students will receive scholarships of up to $5,000.
rareRelated
-
(-)- Epicatechin Becker Muscular DystrophyThis is a 48-week open-label extension o...
-
Analysis of a Virtual Reality Task in Patients With Duchenne Muscular DystrophyThe task consists in reach as much bubbl...
-
Revatio for Heart Disease in Duchenne Muscular Dystrophy and Becker Muscular DystrophyThis study, supported by Charley's Fund,...
-
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne M...This is a Phase 2 randomized, 2-period, ...
-
There’s No Straight Line in Drug DevelopmentToday’s FDA disapproval of Sarepta’s...
-
Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular DystrophyThis is a Phase 1, double-blind, placebo...
-
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy (PolarisDMD)The PolarisDMD study is a Phase 3, globa...
-
An Update on Clinical Trial Innovation for Duchenne – a Master Protocol SharePPMD is committed to making research and...
-
Cardiac and Skeletal Muscle Effects in the Randomized HOPE-Duchenne TrialObjective: To assess the feasibility, s...
-
Sarepta Receives Negative CHMP Re-examination Opinion for EteplirsenSarepta Therapeutics, Inc., a commercial...
-
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to strengthen FDA’s expanded access programSince the 1970s, the FDA has helped to f...
